Solabia acquires majority stake in BioActor

Paris, France, January 12th, 2023

Press release
Solabia strengthens its position in the nutrition market with the acquisition of a majority stake in BioActor, a leader in the development and commercialisation of clinically proven natural active ingredients used by leading food supplement brands.

Founded in 2011 and located on the Maastricht Health Campus, BioActor is an innovation leader in the development and commercialisation of clinically evaluated polyphenols extracted from edible plants and fruits and used by leading food supplement brands worldwide.

Thanks to an in-house clinical research team with direct access to a state-of-the-art clinical research facility and a genuine passion for innovation, BioActor’s health ingredients are all first-in-class, offering supplement brands the opportunity to develop unique solutions to consumers worldwide. BioActor currently exports to more than 20 countries worldwide, serving leading brands across the nutrition and supplement industries.

Solabia is already present in the nutrition segment through original ingredients recognized for their health benefits, including Algatech’s microalgae-derived active ingredients. This strategic investment will allow Solabia to benefit from a wider range of ingredients and from BioActor’s expertise, strengthening its nutrition division positioning on this fast-growing market, as customers increasingly look for high quality active ingredients that combine naturality with proof of efficacy.

This new partnership will also support BioActor’s continued focus on R&D and product development, as well as the expansion of its production capabilities, enabling the company to serve the increasing global demand for its products. BioActor will become a centre of excellence for innovation and clinical research within Solabia’s nutrition division and the combination will allow both companies to benefit from the combined network and expertise, as well as to access new marketing channels and an expanded customer base.

Hans van der Saag, BioActor’s founder and CEO, retains a minority share and his role as CEO of BioActor.

Commenting on the acquisition, Jean-Baptiste Dellon, Chief Executive Officer of Solabia, said:
We are very impressed by BioActor’s dynamic team and innovation engine, and we are very pleased to welcome them to Solabia. BioActor’s pioneering R&D, impressive clinical research capabilities, market leading product portfolio and established customer base will allow us to further strengthen our position in the nutrition and food supplement markets. We are looking forward to working with BioActor to enhance growth for current product portfolio and accelerate the development of new ingredients.

Hans van der Saag, Founder & Chief Executive Officer of BioActor, commented:
We are excited to announce BioActor’s acquisition by Solabia. It marks a significant milestone for the company and the people behind its success, and it is an important step towards realising our mission to bring unique and clinically evaluated health ingredients to consumers worldwide. I am also thankful for the hard work and dedication of our employees. Together with Solabia, we are poised to extend the BioActor growth story as part of a larger organisation with an extensive global footprint, a shared commitment to innovation, research and development, and an unwavering focus on utilising the benefits of nutrition to elevate the health of all of us.

About Solabia
Solabia is a vertically integrated manufacturer of natural active ingredients for the cosmetics, nutraceutical, pharmaceutical, biotechnology and microbiology industries. With eight production facilities and multiple R&D centres, Solabia is a major player in the global cosmetics and nutraceutical ingredient markets with presence in North and South America, Europe, Asia, Middle East and Africa. Solabia also produces culture media, supplements, detection kits for the food testing and pharmaceutical industries and for microbiology laboratories.

More information about Solabia can be found at:

About BioActor
BioActor is an innovation leader in the development, and commercialisation of clinically evaluated polyphenols extracted from edible plants and fruits. Based at the Maastricht Health Campus at walking distance from the largest nutrition & health faculty of The Netherlands and the Maastricht University Medical Center, the Company has an in-house clinical research team with direct access a state-of-the-art clinical research facility. Since its inception in 2011, BioActor has developed 8 branded health ingredients, supported by more than 20 clinical studies. The company currently exports its products to leading brands in more than 20 countries worldwide across the nutrition, food and beverages industries.

More information about BioActor can be found at:

For more information, please contact:

Françoise Pestretzoff

Hans van der Saag